Makes Keytruda, the world's best-selling cancer drug, plus vaccines and animal health products.
$147.24close as of 2026-10-22
+73.0% over 1Y · 57.4 points ahead of the S&P 500
MRKS&P 500 (SPY), rebased to MRK's first close
“Can Winrevair, Lipfendra and Merck’s acquired pipeline broaden growth while Keytruda still supplies much of its revenue?”
Editorial note · updated 2026-10-02
The TenQ Radar
Merck in 36 checks
Merck on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
A mixed picture, with strengths and real weaknesses: 20 of 36 checks passed.
The Merck story
What drives Merck, what its price assumes and what could change the story, written from its own filings.
Keytruda remains central. Keytruda and Keytruda Qlex generated $8.4 billion of Merck’s $16.6 billion in revenue in the quarter to June 2026.
Expansion carries costs. The $6.8 billion Terns acquisition added an investigational leukemia medicine but also produced a charge that drove losses under both GAAP and non-GAAP accounting in the quarter to June 2026.
Faster cash growth assumed. The share price implies free cash flow after stock pay grows 10.1% a year for ten years, compared with 3.2% annually over the last 10 years.
Q2 '26 · quarter to 30 June 2026 · reported 4 August 2026 · Earnings release ↗
Revenue$16.6B+5.1%vs 2025+2.0%vs Q1
Earnings-$1.3B-$5.8Bvs 2025+$2.9Bvs Q1
Against its own guidance
Full year 2026▲Raised its outlook by 0.6%
Was $65.8B to $67.0B
Now $66.3B to $67.3B
Measured at the midpoint, against the range it guided in April 2026. +2.8% on 2025.
What the release says
Highlights
Merck reported strong sales growth in oncology, with KEYTRUDA/KEYTRUDA QLEX sales reaching $8.4 billion (5% growth), including $463 million from the new KEYTRUDA QLEX formulation.
WINREVAIR sales grew 75% year-over-year to $588 million, reflecting continued uptake in the U.S. and early launches in Japan and Europe.
The company received U.S. FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor for hypercholesterolemia, and announced positive late-stage trial results for new oncology and HIV treatments.
GAAP and non-GAAP loss per share were impacted by a $2.31 per share charge related to the $6.8 billion acquisition of Terns Pharmaceuticals, which added MK-4208 to the pipeline.
What management expects
Merck raised and narrowed its full-year 2026 sales outlook to a range of $66.3 billion to $67.3 billion, including a positive impact from foreign exchange of approximately 1%.
The company now expects full-year 2026 non-GAAP EPS to be between $2.66 and $2.76, including one-time charges of $3.62 per share for the acquisition of Cidara and $2.31 per share for the acquisition of Terns, as well as $0.12 per share in costs to finance the Terns acquisition and advance MK-4208.
The full-year non-GAAP effective income tax rate is expected to be between 35.0% and 36.0%, reflecting the impact of non-tax deductible one-time charges for the acquisitions of Cidara and Terns.
Key risks
Merck is highly dependent on patent rights for its key products, and loss or invalidation of these patents could lead to significant and rapid declines in sales, especially for products like KEYTRUDA, Januvia, Janumet, and Bridion as they lose market exclusivity.
Key products such as KEYTRUDA, Gardasil/Gardasil 9, Lynparza, Winrevair, and Bravecto generate a significant portion of profits and cash flows, so any adverse events affecting these products or their markets could materially impact results.
The company faces continued pricing pressure globally, including from U.S. government price setting under the IRA, managed care organizations, and international government pricing actions, which could negatively affect sales and profit margins.
Merck's business in China experienced significantly lower sales of Gardasil/Gardasil 9 in 2025, and the company expects that sales in China will not materially increase in 2026, which has led to a significant decline in its business in that market.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Merck reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●1/6
Expensive against its own history and its sector: the price asks a lot of the business.
116.3xown 10-year median 20.5x
5.5xown 10-year median 3.4x
4.4%cash earned per $ of price
37.6xwhole-business multiple
Valuation history
Is MRK's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2016
28.4742
2.804
2.7843
2017
51.2499
3.058
3.5733
2018
20.4732
3.0109
4.7692
2019
16.4136
4.1297
6.2361
2020
22.7886
3.879
6.3612
2021
12.5481
3.3619
4.2882
2022
13.829
3.3869
4.3657
2023
683.2736
4.1486
6.6362
2024
16.3204
4.3535
6.0319
2025
11.496
3.2279
3.989
2026
116.3349
5.457
8.663
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 116.3x earnings, the market is paying +468% more than MRK's own 10-year median of 20.5x. Expectations are elevated, so more has to go right to justify the price.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Earnings yield
Does MRK's earnings yield beat a 10-year Treasury?
Period
Earnings yield
10-year Treasury
2016
0.0351
0.0183
2017
0.0195
0.0233
2018
0.0488
0.0289
2019
0.0609
0.0208
2020
0.0439
0.0083
2021
0.0797
0.0146
2022
0.0723
0.03
2023
0.0015
0.0397
2024
0.0613
0.0424
2025
0.087
0.0425
2026
0.0086
0.0513
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it · the Treasury line is the average 10-year yield over the same year or quarter, and today's yield at the last point
→At today's price, MRK earns 0.9% of its share price in profit a year, less than the 5.1% a 10-year Treasury pays.
What this measures
Earnings yield is profit per share divided by the share price: 1 ÷ P/E. It is the profit you buy with each dollar of share price. The 10-year US Treasury yield is what the government pays, with no risk to the payment, for lending to it for ten years.
What good looks like. An earnings yield above the Treasury yield: each dollar in the shares buys more profit than the same dollar earns in a government bond.
If it rises or falls. It falls when the share price rises faster than profit, and the bar rises when interest rates do: a higher Treasury yield makes the same shares harder to justify. A company whose profit is growing fast can sit below the line for years, which is what the price is betting on.
Free cash flow yield
What is MRK's free cash flow yield at today's price?
Period
FCF yield
2016
0.0785
2017
0.0372
2018
0.0652
2019
0.0623
2020
0.0362
2021
0.053
2022
0.0732
2023
0.0367
2024
0.0648
2025
0.0589
2026
0.0442
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys 4.4% of annual free cash flow, less than its 10-year median of 6.2% - you are paying up for the same cash.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
Reverse discounted cash flow
What growth is priced into MRK's shares?
Growth priced infree cash flow after stock pay, a year, next ten years10.1%
Growth deliveredfree cash flow after stock pay, a year, last 10 years3.2%
What the check allowsits record, slowing halfway to the economy's 4%3.6%
Growth priced in: free cash flow after stock pay, a year, next ten years
0.1013
Growth delivered: free cash flow after stock pay, a year, last 10 years
0.0324
What the check allows: its record, slowing halfway to the economy's 4%
0.0362
◌ Discounted at 10.1%: the 10-year Treasury yield (5.1%) plus 5 points, then 2.5% a year after year ten. Delivered growth compares the average of the latest three fiscal years with the three 10 years earlier: one year's free cash flow swings too much to measure a decade from.
→At $147.24 a share, MRK's price assumes its free cash flow after stock pay grows 10.1% a year for the next ten years. Over the last 10 years it grew 3.2% a year. Allowing for that pace to slow, the check asks for no more than 3.6%: the price asks for more. The company guides revenue up about 3% for its next fiscal year.
What this measures
A reverse discounted cash flow. It takes what the market pays for the shares today (market value less the cash the company holds) and works out how fast free cash flow would have to grow each year, for ten years, to be worth exactly that. Free cash flow here is after the stock the company pays its staff, which dilutes every other shareholder, and after interest, so debt is already paid for in it. Future cash is discounted at the 10-year Treasury yield plus 5 points, and grows 2.5% a year after year ten.
What good looks like. A priced-in rate below what its record suggests: the free cash flow growth it delivered over the longest span its filings allow, slowed halfway toward the economy's growth, because very few companies keep a past pace for another decade.
If it rises or falls. It rises when the share price rises or free cash flow falls, and when interest rates rise: a higher Treasury yield means the same price needs more growth to justify it.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
10.1% a year priced in vs 3.6%: 3.2% free cash flow growth over the last 10 years, slowing halfway to 4.0%
II
Growth
●●●●●●2/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
+4.6%vs the year before
+3.1%compound annual
-80.7%net income growth
+7.9%compound annual
Revenue history
Is MRK's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q2 2017
9.93B
Q3 2017
10.32B
Q1 2018
10.04B
Q2 2018
10.46B
Q3 2018
10.79B
Q4 2018
11.00B
Q1 2019
10.82B
Q2 2019
11.76B
Q3 2019
12.40B
Q1 2020
12.06B
Q2 2020
9.35B
Q3 2020
10.93B
Q1 2021
10.63B
Q2 2021
11.40B
Q3 2021
13.15B
Q4 2021
13.52B
Q1 2022
15.90B
Q2 2022
14.59B
Q3 2022
14.96B
Q4 2022
13.83B
Q1 2023
14.49B
Q2 2023
15.04B
Q3 2023
15.96B
Q4 2023
14.63B
Q1 2024
15.78B
Q2 2024
16.11B
Q3 2024
16.66B
Q4 2024
15.62B
Q1 2025
15.53B
Q2 2025
15.81B
Q3 2025
17.28B
Q4 2025
16.40B
Q1 2026
16.29B
Q2 2026
16.61B
2007
24.20B
2008
23.85B
2009
27.43B
2010
45.99B
2016
39.81B
2017
40.12B
2018
42.29B
2019
39.12B
2020
41.52B
2021
48.70B
2022
59.28B
2023
60.12B
2024
64.17B
2025
65.01B
→Revenue reached $65.0B in 2025, compounding +3% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $66.6B, ahead of the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Profit history
Is MRK's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q3 2011
1.69B
Q4 2011
1.51B
Q1 2012
1.74B
Q2 2012
1.79B
Q3 2012
1.73B
Q4 2012
908.0M
Q1 2013
1.59B
Q2 2013
906.0M
Q3 2013
1.12B
Q4 2013
781.0M
Q1 2014
1.71B
Q2 2014
2.00B
Q3 2014
895.0M
Q4 2014
7.32B
Q1 2015
953.0M
Q2 2015
687.0M
Q3 2015
1.83B
Q4 2015
976.0M
Q1 2016
1.13B
Q2 2016
1.21B
Q3 2016
2.18B
Q4 2016
-594.0M
Q1 2017
1.55B
Q2 2017
1.95B
Q3 2017
-56.0M
Q4 2017
-1.05B
Q1 2018
736.0M
Q2 2018
1.71B
Q3 2018
1.95B
Q4 2018
1.83B
Q1 2019
2.92B
Q2 2019
2.67B
Q3 2019
1.90B
Q4 2019
2.36B
Q1 2020
3.22B
Q2 2020
3.00B
Q3 2020
2.94B
Q4 2020
-2.10B
Q1 2021
3.18B
Q2 2021
1.54B
Q3 2021
4.57B
Q4 2021
3.76B
Q1 2022
4.31B
Q2 2022
3.94B
Q3 2022
3.25B
Q4 2022
3.02B
Q1 2023
2.82B
Q2 2023
-5.97B
Q3 2023
4.75B
Q4 2023
-1.23B
Q1 2024
4.76B
Q2 2024
5.46B
Q3 2024
3.16B
Q4 2024
3.74B
Q1 2025
5.08B
Q2 2025
4.43B
Q3 2025
5.79B
Q4 2025
2.96B
Q1 2026
-4.24B
Q2 2026
-1.33B
2011
6.27B
2012
6.17B
2013
4.40B
2014
11.92B
2015
4.44B
2016
3.92B
2017
2.39B
2018
6.22B
2019
9.84B
2020
7.07B
2021
13.05B
2022
14.52B
2023
365.0M
2024
17.12B
2025
18.25B
→Net income was $18.3B in 2025, compounding +8% a year over three years. Earnings per share moved -81% over the last twelve months. Trailing twelve-month profit stands at $3.2B.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are MRK's revenue and earnings growing?
Shown separately because they would flatten the axis: 2024 earnings +4590% - rebounds off a collapsed prior year.
Year
Revenue growth
Earnings growth
2,008
-0.0144
-
2,009
0.15
-
2,010
0.6766
-
2,016
-0.1344
-0.1175
2,017
0.0079
-0.3893
2,018
0.0541
1.5982
2,019
-0.075
0.5825
2,020
0.0613
-0.282
2,021
0.1731
0.8465
2,022
0.2172
0.1127
2,023
0.014
-0.9749
2,024
0.0674
-
2,025
0.0131
0.0664
2026
0.0464
-0.8066
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue grew 5% over the twelve months to 2026-06-30, against an average of +10% a year over 2021-2025. Earnings went the other way (fell 81%) even as sales grew, so margins compressed: costs rose faster than revenue.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are MRK's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,016
14.2831
3.1439
2,017
14.6004
1.6605
2,018
15.7872
3.1008
2,019
15.1632
3.9035
2,020
16.3392
2.292
2,021
19.1899
3.4177
2,022
23.3214
5.7856
2,023
23.6023
3.5897
2,024
25.253
7.1216
2,025
25.9318
4.9302
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $25.93 in 2025, compounding +4% a year - in line with MRK's own +3%, so the share count is not distorting your slice. The trailing twelve months are running at $26.55 a share. Free cash flow per share stands at $4.93.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
Revenue by regionInsight
How much of Merck's revenue is outside the US?
dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
→China is $408M of Merck's $16.6B. It is small against the $9.4B the company earns at home, and small enough that one product withdrawn from one market moves the line you can see here.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
Revenue by segmentInsight
How big is Merck's animal health business?
dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
→Pharmaceutical is $14.8B of Merck's $16.5B, 89% of it, against $1.8B for Animal Health. The vaccines and cancer drugs are the company; the vet business is about a tenth of it.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
→Keytruda sold $8.4B in Q2 2026, out of $16.6B of Merck's total sales: that much of the company rests on one cancer drug, whose main US patent runs out in 2028.
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
A solidly profitable business, though not exceptional against its sector.
73.0%kept after direct costs
11.6%kept after running costs
6.6%profit on shareholders' money
7.5%against a 10% cost of capital
629%operating cash ÷ net income
Margins
What profit margin does MRK keep on each sale?
Year
Gross
Operating
Net
2,007
0.7462
-
0.1354
2,008
0.7659
-
0.3274
2,009
0.6712
-
0.4703
2,010
0.6
-
0.0187
2,016
0.6475
-
0.0985
2,017
0.6782
-
0.0597
2,018
0.6806
-
0.1471
2,019
0.6929
-
0.2516
2,020
0.672
-
0.1702
2,021
0.7202
-
0.2679
2,022
0.7063
-
0.2449
2,023
0.7317
-
0.0061
2,024
0.7632
-
0.2668
2,025
0.748
-
0.2808
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Net margin stands at 28% in 2025. MRK doesn't break out gross or operating margin in its filings, so net is the only layer the data supports.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does MRK's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,011
12.38B
6.27B
2,012
10.02B
6.17B
2,013
11.65B
4.40B
2,014
7.99B
11.92B
2,015
12.54B
4.44B
2,016
10.38B
3.92B
2,017
6.45B
2.39B
2,018
10.92B
6.22B
2,019
13.44B
9.84B
2,020
10.25B
7.07B
2,021
13.12B
13.05B
2,022
19.09B
14.52B
2,023
13.01B
365.0M
2,024
21.47B
17.12B
2,025
16.47B
18.25B
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating cash flow runs at 629% of reported profit, so the earnings are more than backed by cash - depreciation and other non-cash charges are understating what the business actually collects.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does MRK earn?
Year
ROE
ROA
ROCE
2,011
0.1152
0.0597
-
2,012
0.1147
0.0581
-
2,013
0.0857
0.0417
-
2,014
0.2422
0.1214
-
2,015
0.0952
0.0437
-
2,016
0.0925
0.0411
-
2,017
0.0643
0.0272
-
2,018
0.2038
0.0753
-
2,019
0.3742
0.1166
-
2,020
0.2759
0.0772
-
2,021
0.411
0.1235
-
2,022
0.345
0.133
-
2,023
0.0087
0.0034
-
2,024
0.4081
0.1462
-
2,025
0.3691
0.1334
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of 7% and ROCE of 8% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Income waterfall
Where does MRK's revenue go, from sales to net profit?
Step
Amount ($)
Revenue, last 12m
66.57B
Gross profit
48.57B
Operating income
7.69B
Net income
3.17B
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Of $66.6B over the twelve months to 2026-06-30 sales, $48.6B survives production costs, $7.7B survives running the company, and $3.2B - 5¢ of every dollar - reaches the bottom line.
What this measures
One year of revenue, with each major cost taken out in the order the income statement takes it, ending at net profit.
What good looks like. No single step swallowing a surprising share, and a bottom line that survives all of them.
If it rises or falls. The largest step is where the business really spends its money, and it is the one to watch year to year: a step that grows faster than revenue is what margin compression looks like before it reaches the margin chart.
Cash conversion
How much of each sale does MRK turn into free cash flow?
Period
FCF margin
2016
0.2201
2017
0.1137
2018
0.1964
2019
0.2574
2020
0.1403
2021
0.1781
2022
0.2481
2023
0.1521
2024
0.282
2025
0.1901
→19 cents of every sales dollar became free cash in 2025, down 6 points since 2022. The trailing twelve months run at 24 cents.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does MRK spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,016
0.0405
0.2578
0.0075
2,017
0.0471
0.2577
0.0078
2,018
0.0618
0.2306
0.0082
2,019
0.0861
0.2486
0.0099
2,020
0.1067
0.3227
0.0106
2,021
0.0913
0.2514
0.0098
2,022
0.074
0.2285
0.0091
2,023
0.0643
0.5079
0.0107
2,024
0.0525
0.2795
0.0119
2,025
0.0633
0.2429
0.0126
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 24% of revenue (capital spending 6%, stock compensation 1%).
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
→Merck paid $11.0B for Prometheus Biosciences, $10.4B for Verona Pharma, $9.2B for Cidara and $6.8B for Terns.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
The balance sheet carries real risk. Read the checks before anything else.
1.29xborrowed vs owned
1.3xnear-term bills coverage
4xearnings ÷ interest bill
$7.1Bcash plus short-term investments
Debt & cash
How much debt does MRK carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,012
20.57B
16.14B
2,013
25.06B
17.49B
2,014
21.40B
15.72B
2,015
26.41B
13.43B
2,016
24.84B
14.34B
2,017
24.41B
8.50B
2,018
25.10B
8.86B
2,019
26.30B
10.45B
2,020
31.80B
8.05B
2,021
33.10B
8.10B
2,022
30.70B
13.19B
2,023
35.10B
7.09B
2,024
37.10B
13.69B
2,025
49.30B
14.56B
2,026
53.90B
7.14B
◌ each quarterly point is the balance sheet at that quarter end
→Debt of $53.9B sits against $7.1B of cash, or 1.3x shareholders' equity. Earnings cover interest 4.4 times - adequate, with less room than it looks in a downturn.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do MRK's current assets cover the bills due within a year?
Period
Current ratio
2011
2.0425
2012
1.8998
2013
1.9971
2014
1.7723
2015
1.5495
2016
1.7795
2017
1.3305
2018
1.1652
2019
1.2369
2020
1.016
2021
1.2678
2022
1.4737
2023
1.252
2024
1.3646
2025
1.5362
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is adequate but not generous: 1.3x of current assets against a dollar due within the year. That is thinner than in 2011.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of MRK's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2016
0.2607
2017
0.1608
2018
0.2582
2019
0.3435
2020
0.247
2021
0.2694
2022
0.3221
2023
0.2164
2024
0.3346
2025
0.2534
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→30.0% of every dollar MRK sold arrived as operating cash. Up from 26.1% in 2016.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is MRK's shareholder equity (book value) growing?
Period
Equity ($)
2012
53.02B
2013
49.77B
2014
48.65B
2015
44.68B
2016
40.09B
2017
34.34B
2018
26.70B
2019
25.91B
2020
25.32B
2021
38.18B
2022
45.99B
2023
37.58B
2024
46.31B
2025
52.61B
2026
41.93B
→The company's own capital grew from $37.6B in 2023 to $41.9B (+12%). The business is building book value rather than consuming it.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
Shareholders are paid reliably and affordably, and the share count is not eroding their stake.
+1.16%bought back, TTM, over market value
+2.31%at the current rate
$12.5Bdividends plus buybacks
$892Mlast 12m, dilutes the buybacks
-19.6%since 2011 (split-adjusted)
Capital returned vs stock comp
Do MRK's buybacks and dividends outweigh the stock it issues to staff?
Year
Buybacks
Dividends
Stock comp
2,011
1.92B
4.69B
369.0M
2,012
2.59B
5.12B
335.0M
2,013
6.52B
5.16B
276.0M
2,014
7.70B
5.17B
278.0M
2,015
4.19B
5.12B
299.0M
2,016
3.43B
5.12B
300.0M
2,017
4.01B
5.17B
312.0M
2,018
9.09B
5.17B
348.0M
2,019
4.78B
5.70B
388.0M
2,020
1.28B
6.21B
441.0M
2,021
840.0M
6.61B
479.0M
2,022
-
7.01B
541.0M
2,023
1.35B
7.45B
645.0M
2,024
1.31B
7.84B
761.0M
2,025
5.08B
8.18B
820.0M
→Shareholders received $5.1B in buybacks and $8.2B in dividends in 2025. The trailing twelve months come to $12.5B. Stock compensation issued $820M of new shares in the same year, offsetting 6% of that.
What this measures
Cash returned through buybacks and dividends, alongside the value of new shares issued to employees as compensation.
What good looks like. Returns comfortably larger than stock compensation, so the share count actually falls.
If it rises or falls. A company can announce billions in buybacks while issuing nearly as much stock to staff, and the two largely cancel. What reaches you is the net effect, which is why both bars are here rather than only the buyback.
Shareholder yield
What is MRK's shareholder yield from dividends and buybacks?
Year
Buyback yield
Dividend yield
2,016
0.0308
0.0459
2,017
0.0327
0.0421
2,018
0.0714
0.0406
2,019
0.0296
0.0353
2,020
0.008
0.0386
2,021
0.0051
0.0404
2,022
0
0.0349
2,023
0.0054
0.0299
2,024
0.0047
0.0281
2,025
0.0242
0.039
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→MRK handed back 3.5% of its market value over the last twelve months, above the 2% this check asks for. Split between buybacks (1.2%) and the dividend (2.3%). Its own average is 6.3%, so less is coming back than usual.
What this measures
Dividends and buybacks, each as a percentage of what the company was worth that year. The dollar chart says how much came back; this says how much came back for the price.
What good looks like. A total that clears a couple of percent and holds. Which half it comes from matters less than whether it is sustained.
If it rises or falls. A yield rises when the price falls as readily as when the payout grows, so read a jump beside the price chart before treating it as generosity.
Share count change (split-adjusted)
Is MRK's share count rising or falling?
Year
Share-count change
2,012
-0.0058
2,013
-0.026
2,014
-0.0227
2,015
-0.0297
2,016
-0.019
2,017
-0.014
2,018
-0.0251
2,019
-0.037
2,020
-0.0151
2,021
-0.0012
2,022
0.0016
2,023
0.002
2,024
-0.0024
2,025
-0.0134
→The share count shrank 1.3% in 2025, averaging 0.5% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dividend per share (split-adjusted)
Is MRK's dividend per share growing?
Year
DPS ($)
2,011
1.5162
2,012
1.6632
2,013
1.7213
2,014
1.7657
2,015
1.8011
2,016
1.8385
2,017
1.8803
2,018
1.9306
2,019
2.2074
2,020
2.4459
2,021
2.6044
2,022
2.7585
2,023
2.923
2,024
3.0854
2,025
3.2613
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, the dividend paid over the trailing twelve months, or in the single quarter, over that quarter's diluted share count
→The dividend per share reached $3.26 in 2025, compounding +6% a year since 2020.
What this measures
The dividend paid on one share each year, adjusted for splits so a share today compares with a share ten years ago.
What good looks like. A payment that rises steadily. A long unbroken run of rises is a management commitment as much as a number.
If it rises or falls. A cut is one of the strongest signals a board can send, because they know how it will be read. Check it against the payout chart: a rising dividend the business cannot cover is a promise borrowed against.
Dividend yield
What is MRK's dividend yield at today's price?
Year
Yield
2016
0.0459
2017
0.0421
2018
0.0406
2019
0.0353
2020
0.0386
2021
0.0404
2022
0.0349
2023
0.0299
2024
0.0281
2025
0.039
2026
0.0231
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→MRK's dividend at its current rate is 2.31% of today's price.
What this measures
The dividend paid over the trailing twelve months as a percentage of the share price, at each quarter's (or year's) average price and at today's.
What good looks like. A yield in line with the company's own history. A yield far above it is usually the price falling, not the dividend rising.
If it rises or falls. Yield moves for two opposite reasons, and they are easy to confuse: a bigger dividend, or a cheaper share. The dividend-per-share chart above tells you which one happened.
Payout quality
What share of its profit and cash does MRK pay out as dividends?
Year
Of profits
Of free cash flow
2,011
0.7479
0.4401
2,012
0.8294
0.6341
2,013
1.171
0.5103
2,014
0.4337
0.7749
2,015
1.152
0.4546
2,016
1.3071
0.5848
2,017
2.1583
1.1324
2,018
0.8315
0.6226
2,019
0.5786
0.5655
2,020
0.8794
1.0671
2,021
0.5066
0.762
2,022
0.483
0.4768
2,024
0.458
0.4332
2,025
0.4479
0.6615
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The dividend consumed 45% of profit and 66% of free cash flow in 2025. Over the trailing twelve months it is 262%. That leaves room to keep paying through a weak year.
What this measures
The dividend as a share of profit, and as a share of free cash flow. Two views of the same question, because profit and cash are not the same thing.
What good looks like. Comfortably under 75% of profit and under 90% of free cash flow, which leaves room to keep paying through a weak year.
If it rises or falls. A payout ratio climbing towards 100% means the dividend is consuming everything the business earns, so the next bad year has to be funded by borrowing or by a cut. Above 100% it is already being funded from somewhere else.
Dilution against what it bought
Has MRK's revenue per share grown faster than its share count?
Change since 2016. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2016
Revenue per share, change since 2016
2,016
0
0
2,017
-0.014
0.0222
2,018
-0.0388
0.1053
2,019
-0.0743
0.0616
2,020
-0.0883
0.144
2,021
-0.0893
0.3435
2,022
-0.0879
0.6328
2,023
-0.0861
0.6525
2,024
-0.0883
0.768
2,025
-0.1005
0.8156
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→MRK has shrunk its share count 19% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is up 82% over the same years.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→MRK is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are MRK's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
0
4.8M
2023-12
0
0
2024-01
0
0
2024-02
0
51.6M
2024-03
0
0
2024-04
0
0
2024-05
0
0
2024-06
0
0
2024-07
0
0
2024-08
0
0
2024-09
0
0
2024-10
0
0
2024-11
0
0
2024-12
0
0
2025-01
0
0
2025-02
1.6M
1.4M
2025-03
0
0
2025-04
0
352,723
2025-05
0
0
2025-06
0
0
2025-07
0
0
2025-08
0
0
2025-09
0
0
2025-10
0
0
2025-11
0
1.3M
2025-12
0
0
2026-01
0
0
2026-02
0
40.7M
2026-03
0
0
2026-04
0
0
2026-05
0
0
2026-06
0
0
2026-07
0
0
2026-08
0
30.0M
2026-09
0
0
2026-10
0
0
→Since November 2023, insiders bought $2M and sold $130M on the open market, a net sale of $129M. A further 128 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-08-13
Chirfi Guindo
EVP, Access, Policy & Comms
SELL
10,000
$135.00
$1.35M
2026-08-12
Jennifer Zachary
EVP, General Counsel
exercise
41,494
$117.89
$4.89M
2026-08-12
Jennifer Zachary
EVP, General Counsel
exercise
13,433
$84.71
$1.14M
2026-08-12
Jennifer Zachary
EVP, General Counsel
SELL
80,315
$133.46
$10.72M
2026-08-12
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
11,099
$131.61
$1.46M
2026-08-12
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
600
$132.04
$79,222
2026-08-11
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
7,410
$131.33
$973,165
2026-08-11
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
5,427
$132.35
$718,261
2026-08-10
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
20,784
$130.43
$2.71M
2026-08-06
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
805
$131.02
$105,472
2026-08-06
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
4,945
$130.23
$643,993
2026-08-06
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
SELL
300
$131.02
$39,307
2026-08-06
Chirfi Guindo
EVP, Access, Policy & Comms
SELL
15,000
$131.00
$1.97M
2026-08-05
David R. Maraldo
EVP & Pres. MMD
exercise
6,311
$73.73
$465,310
2026-08-05
David R. Maraldo
EVP & Pres. MMD
SELL
6,311
$128.72
$812,339
2026-08-05
David R. Maraldo
EVP & Pres. MMD
exercise
9,709
$87.10
$845,654
2026-08-05
David R. Maraldo
EVP & Pres. MMD
SELL
9,709
$128.72
$1.25M
2026-08-05
David R. Maraldo
EVP & Pres. MMD
exercise
2,686
$84.71
$227,531
2026-08-05
David R. Maraldo
EVP & Pres. MMD
SELL
2,686
$128.72
$345,736
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
exercise
4,600
$77.62
$357,052
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
SELL
4,600
$128.77
$592,345
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
exercise
13,542
$75.36
$1.02M
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
SELL
13,542
$128.77
$1.74M
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
exercise
34,705
$73.73
$2.56M
2026-08-05
David Michael Williams
EVP,Chief Info&Digital Officer
SELL
34,705
$128.77
$4.47M
2026-05-02
Dalton E. Smart III
SVP Fin. - Global Controller
exercise
383
$112.16
$42,957
2026-05-02
Dalton E. Smart III
SVP Fin. - Global Controller
tax
132
$112.16
$14,805
2026-05-02
David R. Maraldo
EVP & Pres. MMD
exercise
552
$112.16
$61,912
2026-05-02
David R. Maraldo
EVP & Pres. MMD
tax
159
$112.16
$17,833
2026-04-30
Dalton E. Smart III
SVP Fin. - Global Controller
exercise
464
$110.95
$51,481
2026-04-30
Dalton E. Smart III
SVP Fin. - Global Controller
tax
159
$110.95
$17,641
2026-04-30
Betty D Larson
EVP, Chief HR Officer
exercise
11,350
$110.95
$1.26M
2026-04-30
Betty D Larson
EVP, Chief HR Officer
tax
5,143
$110.95
$570,616
2026-04-29
Chirfi Guindo
EVP, Access, Policy & Comms
exercise
1,967
$110.03
$216,429
2026-04-29
Chirfi Guindo
EVP, Access, Policy & Comms
tax
969
$110.03
$106,619
2026-04-29
Sanat Chattopadhyay
Exe V-P & Pres. MMD
exercise
2,597
$110.03
$285,748
2026-04-29
Sanat Chattopadhyay
Exe V-P & Pres. MMD
tax
1,130
$110.03
$124,334
2026-04-29
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
exercise
2,518
$110.03
$277,056
2026-04-29
Richard R. Deluca
EVP&Pres, Merck Animal Heallth
tax
1,241
$110.03
$136,547
2026-04-29
David Michael Williams
EVP,Chief Info&Digital Officer
exercise
1,377
$110.03
$151,511
2026-04-29
David Michael Williams
EVP,Chief Info&Digital Officer
tax
679
$110.03
$74,710
2026-04-29
Dalton E. Smart III
SVP Fin. - Global Controller
exercise
944
$110.03
$103,868
2026-04-29
Dalton E. Smart III
SVP Fin. - Global Controller
tax
324
$110.03
$35,650
2026-04-29
Dean Y Li
Executive VP & President, MRL
exercise
4,722
$110.03
$519,562
2026-04-29
Dean Y Li
Executive VP & President, MRL
tax
2,326
$110.03
$255,930
2026-04-29
Jennifer Zachary
EVP, General Counsel
exercise
2,951
$110.03
$324,699
2026-04-29
Jennifer Zachary
EVP, General Counsel
tax
1,454
$110.03
$159,984
2026-04-29
Betty D Larson
EVP, Chief HR Officer
exercise
2,085
$110.03
$229,413
2026-04-29
Betty D Larson
EVP, Chief HR Officer
tax
715
$110.03
$78,671
2026-04-29
Caroline Litchfield
EVP & CFO
exercise
3,935
$110.03
$432,968
2026-04-29
Caroline Litchfield
EVP & CFO
tax
1,938
$110.03
$213,238
2026-04-29
Robert M Davis
Chairman, CEO & President
exercise
13,300
$110.03
$1.46M
2026-04-29
Robert M Davis
Chairman, CEO & President
tax
6,551
$110.03
$720,807
2026-04-29
Johannes Jacobus Oosthuizen
EVP, Oncology & Int?l
exercise
1,377
$110.03
$151,511
2026-04-29
Johannes Jacobus Oosthuizen
EVP, Oncology & Int?l
tax
679
$110.03
$74,710
2026-02-12
Chirfi Guindo
Chief Marketing Officer
SELL
10,000
$121.46
$1.21M
2026-02-10
Dean Y Li
Executive VP & President, MRL
SELL
10,235
$117.52
$1.2M
2026-02-09
Chirfi Guindo
Chief Marketing Officer
SELL
10,000
$118.41
$1.18M
2026-02-09
Jennifer Zachary
EVP, General Counsel
exercise
25,946
$119.15
$3.09M
2026-02-09
Jennifer Zachary
EVP, General Counsel
SELL
25,946
$119.15
$3.09M
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
80.3%on Form 13F, 30 June 2026
0.1%officers, directors, founders
37.1%together
8last 12 months
Top holders
Who owns Merck stock?
Fund managers filing Form 13F held 80.3% of the company's shares on 30 June 2026. The largest holder is BlackRock, Inc., with 9.2%. Insiders hold 0.1%.
#
Holder
Stake
Shares
Value
Change
1
BlackRock, Inc.Fund manager
9.20%
227.0M
$33.4B
+0.5%
2
Vanguard Capital Management LLCFund manager
6.54%
161.3M
$23.8B
+0.2%
3
State Street CorpFund manager
4.88%
120.4M
$17.7B
+0.9%
4
Wellington Management Group LLPFund manager
3.50%
86.2M
$12.7B
+2.3%
5
Vanguard Portfolio Management LLCFund manager
2.75%
67.7M
$10.0B
+0.7%
6
Geode Capital Management, LLCFund manager
2.46%
60.7M
$8.9B
+2.0%
7
Charles Schwab Investment Management IncFund manager
2.20%
54.4M
$8.0B
+9.2%
8
Morgan StanleyFund manager
1.97%
48.6M
$7.2B
+2.1%
9
FMR LLCFund manager
1.84%
45.4M
$6.7B
+2.1%
10
JPMorgan Chase & CoFund manager
1.78%
43.9M
$6.5B
-17.2%
11
Fisher Asset Management, LLCFund manager
1.56%
38.5M
$5.7B
+45.7%
12
Norges BankFund manager
1.50%
37.0M
$5.4B
New
13
Bank of America CorpFund manager
1.24%
30.5M
$4.5B
-0.8%
14
Northern Trust CorpFund manager
1.06%
26.3M
$3.9B
-3.0%
15
Goldman Sachs Group IncFund manager
0.89%
22.1M
$3.3B
+9.6%
16
Franklin Resources IncFund manager
0.79%
19.5M
$2.9B
+20.2%
17
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCFund manager
0.79%
19.5M
$2.9B
-4.3%
18
Legal & General Group PlcFund manager
0.77%
18.9M
$2.8B
-3.4%
19
Invesco Ltd.Fund manager
0.75%
18.6M
$2.7B
-14.8%
20
Price T Rowe Associates IncFund manager
0.75%
18.5M
$2.7B
-19.6%
The full list of top holders is free with an account
Source: Periodic Transaction Reports filed with the Clerk of the House under the STOCK Act, within 45 days of a trade. Amounts are the ranges the law asks for. The Senate's reports are not included yet. All Congress trades
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.